

A Natural Product Combination for Alzheimer's Disease

Skyler Saveland

November 24, 2015

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative condition associated with old age. It is the most common cause of dementia, inflicting an increasing social and economic burden. Medications which are currently approved in the United States do not reverse or prevent disease progression. Therefore, new therapies with more dramatic impact are sought.

There has been abundant interest in natural products to treat Alzheimer's. A large number of preclinical studies have demonstrated that many crude natural products have therapeutic potential. Clinical trials have been conducted on a few of these natural products. A number of traditional medicines which are combinations of natural products have been used to treat AD. Dozens of natural products in various combinations are regularly employed around the world, particularly in China, Japan and Korea. Some clinical trials have been conducted that support the usefulness of these combinations. Ascertaining which constituents are responsible for the positive effects, what interactions may be involved, and what role synergism plays, are daunting combinatorial problems.

Prevailing theories of AD causation have focused on the observed biochemical abnormalities of the senile brain. Observations of amyloid- β plaques, acetylcholine (AChE) deficits, tau protein abnormalities, neuroinflammation and oxidative stress, and aberrant signalling cascades leading to neuronal apoptosis have partially elucidated the clinical picture but have failed to produce satisfactory pharmaceuticals. Natural products are rich in substances which target relevant pathways in AD.

Recent research has produced strong evidence that AD may be caused by fungal infection in the central nervous system (CNS). Many natural products which have been investigated for their potential to curb the biochemical abnormalities associated with AD also show promise as antifungal agents.

Here we conduct a review of the available literature in an attempt to determine which natural products are the most promising candidates for AD therapy. Preferred candidates will have success in clinical trial, clean safety profiles and robust biochemical rationale. We propose a combination of the best candidates to be tested in a new RCT.

Contents

1 Background	4
1.1 Conventional Understanding of Alzheimer's Dementia	4

1.1.1	Amyloid- β (AB)	4
1.1.2	Infection	5
2	Clinical Evidence for Combinations of Natural Products	5
2.1	Traditions	5
2.1.1	Kampo	5
2.1.2	TCM	5
2.1.3	Mixtures Used in Other Countries	5
2.2	Yokukansan (YKS)	5
2.3	Di-Tan Decoction (DTD)	7
2.4	Keishi-ka-ryukotsu-borei-to (KRBT)	7
2.5	Chotosan	7
2.6	Kamikohito (KKT)	7
2.7	Ninjin'yoeito (NYT)	8
2.8	Hochuekkito	8
2.9	Zokumei-to (ZMT)	8
2.10	Ba Wei Di Huang Wan (BWD)	8
2.11	Yishen Huazhuo decoction (YHD)	8
3	Clinical Evidence for Individual Natural Products	8
3.1	Salvia	8
3.2	Citrus	9
3.3	Fungi	9
3.3.1	Ganoderma	9
3.3.2	Hericium	9
4	Biochemical Targets	9

4.1	Fungal Infection	9
4.2	Innate Immunity	9
4.3	Amyloid- β	10
4.4	Inflammation	10
4.5	Cholinergic Drugs	10
4.6	Hormonal Therapy	10
5	Challenges	10
6	Conclusion	10

1 Background

Natural products have probably been used as medicine for over 60,000 years. From then until modern times, more than 200,000 natural products and compounds have been discovered. [1] In recent history, modern chemistry has allowed the chemical design of individual molecules for pharmaceutical applications. But, applying individual molecules to chronic neurodegenerative diseases, for instance, has brought scant success. Interest in natural medicine has sustained through the modern era. A majority of drugs derive from natural products. Of 175 small molecules used against cancer up to 2010, 74.8% were not completely synthetic and 48.6%, were directly derived from natural products. [2] Antibiotic and antifungal compounds have come from leads provided by nature. Antibiotic discovery has been dependent on metabolites produced by soil bacteria. Willow bark, the source of aspirin, was used from ancient times. [3] Ethnobotany still provides a rich reservoir of CNS-active pharmacological leads. [4, 5]

Traditional medicines from China, Japan and Korea invariably employ combinations of different materials from plants and fungi. A large number of active components have been identified. [6] Synergistic relationships have been shown between substances in traditional combinations of natural agents. Multiple active components working together may be the key to future AD treatments. [7, 8]

Psychotropic medicines derived from natural products are particularly promising. [9] Significant evidence exists that suggests that NPs may be effective psychotherapeutics. [10] A wealth of NPs are candidates for the treatment of Alzheimer’s in particular. [11] In addition to biochemical target activities, traditional medicine can provide improvements in cognitive impairments, energy/fatigue, mood, and anxiety. [12] Many acetylcholinesterase (ACHE) inhibitors with potential clinical relevance have been discovered from natural products. [13]

1.1 Conventional Understanding of Alzheimer’s Dementia

Alzheimer’s dementia is a disease of old age characterized by slow onset with a progressive loss of cognitive function with a gradual decline into dementia. AD is considered the most common cause of dementia. The time from diagnosis until death is usually 8-10 years. The most notable pathological changes are plaques of misfolded proteins and neurofibrillary tangles.

1.1.1 Amyloid- β (AB)

The cerebral deposition of amyloid- β protein in AD patients has been recognized for decades. These proteins, which begin to accumulate for years or even decades before the onset of dementia, have long been considered central to the pathology of AD. [14]

A popular hypothesis states that AB is the causative agent in AD, causing the cascade of abnormality observed. Genetic mutations which cause abnormal amyloid precursor protein (APP) are implicated. AB is neurotoxic and could lead to the neurofibrillary tangles and ultimately the death of neurons. [15]

Soluble AB was strongly correlated with AD severity. Measures of insoluble AB could distinguish AD patients from controls; but, could not predict AD severity. AB is usually thought of as extracellular. However, soluble AB can be extracellular or intracellular. [16]

More recently, synaptotoxic AB oligomers have been implicated in AD biopathology, triggering the accumulation of reactive oxygen species (ROSs). This provides an explanation for the therapeutic action of memantine. [17]

A idea related to AB toxicity is that disturbed microcirculation in the brain causes AD. [18]

1.1.2 Infection

The idea that infections cause AD has been widely studied and has not been ruled out. In fact, a substantial amount of evidence suggests that AD may be caused by infection. [19] Histopathological hallmarks of AD are known to occur in chronic infections, including those of the CNS. [20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31] In addition, evidence has emerged that AB is antimicrobial and may be produced as an innate immune response to infection. [32]

2 Clinical Evidence for Combinations of Natural Products

Many different traditional mixtures exist which are used treat AD. The mixtures have many overlapping components.

Table 1 shows the degree of overlap between individual natural products and some traditional mixtures.

2.1 Traditions

2.1.1 Kampo

Kampo medicine, a traditional medicine of Japan, is a complex system of individualized diagnosis and treatment. An important component of Kampo is precise formulations of natural products based on older Chinese recipes. 148 or more combinations are covered by the national health insurance system in Japan. Of 135 published randomized controlled trials on Kampo combinations published between 1986 and 2007, 37 were available in English. As chronic degenerative diseases have become more prominent in an aging population, interest in Kampo has increased as has Kampo's integration into modern medical practice. A recent survey indicated that 70% of Japanese physicians prescribe Kampo for-

mulations. Insurance-covered formulations include standardized extracts and crude decoctions. Applying Kampo formulations to conventional diagnoses is a challenge because in traditional Kampo, the same conventional diagnosis could result in the prescription of different formulations while different conventional diagnoses could result in the prescription of the same formulation. [33] However, Kampo may evolve based on new scientific evidence. [34]

The testing specific individual formulations on a specific conventional diagnosis is useful for applying Kampo formulations in clinical practice in countries like the United States where expert Kampo practitioners are few. Therefore, for the purposed of this review, the best evidence will be considered to be randomized, placebo-controlled clinical trials on specific formulations for the specific diagnosis of AD.

2.1.2 TCM

A review of Chinese Herbal Medicine for the management of vascular dementia (VD), a disease similar to AD, was conducted, highlighting the urgent need for more clinical trials of high quality. [?]

2.1.3 Mixtures Used in Other Countries

2.2 Yokukansan (YKS)

Yokukansan is a mixture of seven crude natural products, *Atractylodes lanceae* rhizoma, *Poria cocos* sclerotia, *Cnidii* rhizoma, *Angelicae radix*, *Bupleuri radix*, *Glycyrrhizae radix*, and *Uncariae uncis cum ramulus*. Yokukansan is called *Yi-Gan San* in TCM. [35] Clinical trials have demonstrated Yokukansan's efficacy in treating patients with BPSD. Accordingly, Yokukansan has been listed by The Japanese Society of Neurology in the Japanese Guidelines for the Management of Dementia since 2010. A recent review found 13 clinical trials of varying quality included a total of 466 patients that found YKS to be

Genus	YKS	DTD	FMJ	PN-1	SZL	WD	BDW	CMT	HCKT	KRBT	CTS
Poria	X	X	X		X	X	X	X			X
Atractylodis	X								X		
Ligusticum	X										
Angelica	X								X		
Bupleurum	X								X		
Glycyrrhiza	X								X	X	X
Astragalus				X					X		
Uncariae	X										X
Arisaema		X									
Pinellia		X				X		X			
Citrus		X	X			X			X		X
Acorus		X	X		X	X		X			
Ginseng		X							X		X
Bambusa		X				X					
Zingiberis		X							X	X	X
Rehmannia			X				X				
Gastrodia						X					
Ophiopogon			X								X
Anemarrhena			X								
Paeonia			X				X			X	
Dendrobium			X								
Akebia			X								
Cistanche				X							
Codonopsis					X						
Cinnamomum					X		X			X	
Polygala					X			X			
Ostrea										X	
Polygonum						X					
Ziziphus						X			X	X	
Aconitum							X				

Table 1: Mixture to Genus Matrix

a safe and effective way to raise Neuropsychiatric Inventory (NPI) scores. The Mini-Mental State Examination (MMSE) score of cognitive impairment and the Disability Assessment for Dementia (DAD) score of caregiver burden were unimproved, however. [36] Another review of noted improvements in the activities of daily living (ADL) score. [37] Repeated clinical trials have proven the efficacy of YKS in improving NPI and ADL scores in patients with AD. [38]

In a cross-over study of 106 patients to investigate the use of Yokukansan to treat the behavioural and psychological symptoms of dementia (BPSD), a significant improvement in Neuropsychiatric Inventory (NPI) was found. Significant improvements were observed in delusions, hallucinations, agitation/aggression, depression, anxiety, and irritability/lability. Effects were sustained for one month after treatment was ceased. Cognitive function was not significantly improved. [39] In a 52 patient RCT of Yokukansan to treat dementia, BPSD and ADL scores were improved. [35] In an open-label study of 26 patients who received 7.5 grams/day of Yokukansan for 4 weeks, success was seen in reducing hallucinations, agitation, anxiety, irritability and abnormal behavior. But, overall disability and cognitive function were not improved. The mixture was well tolerated. [40]

Yokukansan is considered very safe. In a case series of 3 patients between 10 and 13 years old, YKS considered effective in treating pediatric emotional and behavioral problems within 14-21 days. [41]

2.3 Di-Tan Decoction (DTD)

DTD is a combination of ...

A double-blind, randomized, placebo-controlled, add-on trial testing the efficacy of DTD to treat cognitive impairment in AD patients. [42]

2.4 Keishi-ka-ryukotsu-borei-to (KRBT)

KRBT is a mixture of 7 natural products: cinnamon bark, peony root, jujube fruit, oyster shell, fossilized bone, glycyrrhiza, and ginger rhizome that was found to effectively BPSD in a case report. Gonadotrophin profiles were positively altered. [43]

2.5 Chotosan

Chotosan is a mixture of 11 natural products, *Uncariae Uncis cum Ramulus*, *Aurantii Nobilis pericarpium*, *Pinelliae tuber*, *Ophiopogonis tuber*, *Poria cocos*, *Ginseng radix*, *Saposhnikoviae radix*, *Chrysanthemi flos*, *Glycyrrhizae radix*, *Zingiberis rhizome*, and *Gypsum fibrosum*. Along with YKS, Chotosan has shown promise in clinical and preclinical studies as a treatment for AD. Both mixtures contain *Uncariae Uncis*. [44]

2.6 Kamikohito (KKT)

KKT is composed of 14 crude drugs:

Ginseng Radix (*P. ginseng* C.A. Meyer), *Polygalae Radix* (*P. tenuifolia* Willd.), *Astragali Radix* (*A. membranaceus* Bunge), *Zizyphi Fructus* (*Zizyphus jujube* Mill. var. *inermis* Rehd.), *Zizyphi Spinosi Semen* (*Z. jujube* Mill. var. *spinosa*), *Angelicae Radix* (*Angelica acutiloba* Kitagawa), *Glycyrrhizae Radix* (*Glycyrrhiza uralensis* Fisch), *Atractylodis Rhizoma* (*Atractylodes japonica* Koidzumi ex Kitamura), *Zingiberis Rhizoma* (*Zingiber officinale* Roscoe), *Poria* (*Poria cocos* Wolf), *Saussureae Radix* (*Saussurea lappa* Clarke), *Longanae Arillus* (*Dimocarpus longana*), *Bupleuri Radix* (*Bupleurum falcatum* Linne), and *Gardeniae Fructus* (*Gardenia jasminoides* Ellis). Eleven of the fourteen NPs are listed in 1. *Saussurea*, *Dimocarpus*, and *Gardenia* are unique to KKT.

An animal model revealed that KKT improved

amyloid- β -induced tau phosphorylation and axonal atrophy even after axonal degeneration had progressed. [45, 46]

2.7 Ninjin'yoeito (NYT)

23 patients who had a insufficient response to donepezil received donepezil alone or donepezil and NYT. A 2-year follow-up showed that patients receiving NYT had an improved cognitive outcome and alleviation of AD-related depression. [47]

2.8 Hochuekkito

Hochuekkito is a mix of 10 natural products, Astragali Radix, Atractylodis lanceae Rhizoma, Ginseng Radix, Angelicae Radix, Bupleuri Radix, Zizyphi Fructus, Aurantii Bobilis Pericarpium, Glycyrrhizae Radix, Cimicifugae Rhizoma, and Zingiberis Rhizoma. [48]

In a placebo-controlled clinical trial of Hochuekkito showed that the formulation improved the QOL and immunological status of elderly patients with weakness. [49]

2.9 Zokumei-to (ZMT)

In an animal model of AD using Amyloid- β , ZMT treatment significantly increased the level of expression of synaptophysin up to the control level. Memory impairment and synaptic loss was ameliorated in the mice even after impairment had progressed. [50]

2.10 Ba Wei Di Huang Wan (BWD)

BWD is a traditional Chinese formulation of 8 natural products, Rehmannia glutinosa, Cornus officinalis, Dioscorea batatas root, Alisma orientale rhi-

zome, Poria cocos, Paeonia suffruti-cosa, Cinnamomum cassia, and Aconitum carmichaeli.

In a placebo-controlled RCT of 33 patients with AD, cognitive function was significantly improved by BWD compared to placebo based on the Mini-Mental State Examination (MMSE). The activities of daily living (ADLs) score was also improved versus placebo. Scores returned to baseline after eight weeks. [51]

2.11 Yishen Huazhuo decoction (YHD)

YHD was found to be comparable or better than the conventional AChE drug donepezil

[52]

3 Clinical Evidence for Individual Natural Products

In addition to the traditional formulations, individual constituents are studied for their potential to treat AD including Huperzine, Gingko, Curcuma, Salidroside, Periwinkle-vinca, Centella, Melissa, Polygala, Salvia, and Withania. [53] Investigation in the West has been limited to a few herbs, notably Gingko. Some herbs used in traditional European medicine such as *Salvia officinalis* and *Melissa officinalis* are under investigation for their potential as AD treatments. [5]

3.1 Salvia

Salvia lavandulaefolia (Spanish sage) had strong in vitro antiinflammatory activity relevant to AD. [54] Salvia is a large genus with antifungal properties. [55, 56]

3.2 Citrus

Different species for Citrus are used in traditional medicines which are employed against AD. Typically, the mesocarpium and epicarpium are studied for their neuroprotective, antiinflammatory and antioxidant flavonoids. [?]

Nobiletin-rich Citrus reticulata peels, a kampo medicine for Alzheimer’s disease: A case series [57]

3.3 Fungi

Many mushrooms and other fungi are used around the world for medical purposes. There is a robust scientific rationale suggesting that some fungal products may prove to be effective treatments for AD.

3.3.1 Ganoderma

Aqueous extract of *Ganoderma lucidum* was able to prevent the harmful effects of amyloid- β in an *in vitro* study, preserving the synaptic density protein, synaptophysin in a dose-dependent manner. [58]

Ganoderma lucidum was able to prevent neurotoxicity and hippocampal degeneration while improving cognitive dysfunction in an animal model of AD produced by toxic oxidative stress via streptozotocin (STZ). [59]

Ganoderma lucidum contains small molecules which inhibit AChE. [60]

An immune-modulating polysaccharide from *Ganoderma atrum* was able to attenuate neuronal apoptosis by preventing oxidative damage by modifying the redox system and helping to maintain calcium homeostasis in an animal model. [61]

Learning and memory were improved with administration of *Ganoderma lucidum* in senescent mice, improving antioxidant status. [62]

3.3.2 Hericium

4 Biochemical Targets

4.1 Fungal Infection

Evidence has been put forth that fungal infection is detectable in brain samples from Alzheimer’s disease patients. [63] Recently, fungal infection was directly visualized in the brains of 11 of 11 AD patients and 0 of 10 controls. [64] Misfolded amyloid proteins may originate from a transmissible infectious process (like prion disease). Some proteins behave as prions in yeast and other fungi. [65] Neuroinflammation is associated with innate immunity, intended to fight infection at the blood-brain barrier (BBB). [66] Fungal infection could explain the connection between neuroinflammation, innate immunity and the toxic cell debris associated with AD. Amyloid- β is toxic to yeast cells as well as nerve cells. A yeast model of amyloid toxicity has been proposed because of yeast’s susceptibility to the protein. [67] Conversely, amyloids are also believed to be expressed on fungal cell surfaces. [68] The relationship between amyloid, prion and fungi is complicated. [69]

4.2 Innate Immunity

The innate immune system, preserved from ancient genes, is involved in response to pathogenic fungi. [70] The innate immune system in organisms as diverse as humans and plants is remarkably similar. [71, 72] The signalling cascades involved in innate immune functions are providing insights into infectious disease, autoimmunity and allergy. The innate immune response to many infectious agents is associated with inflammation. [73] Inflammation in AD may be mediated by innate immunity, according to transgenic animal model. [74]

Innate immune response to fungal infection is contributed to by Toll-like receptors (TLRs). [75] Im-

immune response to some pathogenic fungi is dependent on TLRs. [76]

Pathogen associated molecular patterns (PAMPs) are associated with both fungal infection [77] and AD. [78]

4.3 Amyloid- β

An animal model found ZMT effective in reducing Amyloid- β toxicity. [50]

4.4 Inflammation

Long-term use of Non-Steroidal Antiinflammatory Drugs (NSAIDs) have been associated with a dramatic decrease in the risk of AD in a large cohort. The risk ratio was 0.20 (95 percent confidence interval, 0.05 to 0.83). [79]

Other epidemiological evidence suggests that individuals with diets rich in antiinflammatory Curcumin are at lower risk of developing AD. [?]

Inflammation may be the key to initiating the toxic cascade that characterized Alzheimer's rather than the result of misfolded proteins such as amyloid and tau. [80]

4.5 Cholinergic Drugs

Cholinergic drugs were able to slow the progression of AD after 2 years of follow-up. Although, cognitive deterioration was not stopped. [81]

4.6 Hormonal Therapy

Postmenopausal hormone therapy was not found to affect AD risk in a systematic review of epidemiological studies. [82]

5 Challenges

A major concern raised about crude natural products is the challenge of standardization.

A formulation called kamikihito (KKT) in Japan and kami-guibi-tang (KGT) in Korea were comparable in enhancing memory in an animal model, although chromatography revealed differences in the formulations. [46]

6 Conclusion

Write your conclusion here.

References

- [1] H.-F. Ji, X.-J. Li, and H.-Y. Zhang. Natural products and drug discovery. *EMBO reports*, 10(3), 2009.
- [2] D. J. Newman and G. M. Cragg. Natural products as sources of new drugs over the 30 years from 1981 to 2010. *Journal of natural products*, 75(3), 2012.
- [3] J. B. Laursen and J. Nielsen. Phenazine natural products: biosynthesis, synthetic analogues, and biological activity. *Chemical reviews*, 104(3), 2004.
- [4] W. C. McClatchey, G. B. Mahady, B. C. Bennett, L. Shiels, and V. Savo. Ethnobotany as a pharmacological research tool and recent developments in cns-active natural products from ethnobotanical sources. *Pharmacology & therapeutics*, 123(2), 2009.
- [5] E. K. Perry, A. T. Pickering, W. W. Wang, P. J. Houghton, and N. S. Perry. Medicinal plants and alzheimer's disease: from ethnobotany to phytotherapy**. *Journal of Pharmacy and Pharmacology*, 51(5), 1999.

- [6] J. Gao, Y. Inagaki, X. Li, N. Kokudo, and W. Tang. Research progress on natural products from traditional chinese medicine in treatment of alzheimer's disease. *Drug discoveries & therapeutics*, 7(2), 2013.
- [7] D.-X. Kong, X.-J. Li, and H.-Y. Zhang. Where is the hope for drug discovery? let history tell the future. *Drug discovery today*, 14(3), 2009.
- [8] P. Liu, M. Kong, S. Yuan, J. Liu, and P. Wang. History and experience: a survey of traditional chinese medicine treatment for alzheimer's disease. *Evidence-Based Complementary and Alternative Medicine*, 2014, 2014.
- [9] J. Lake. Psychotropic medications from natural products: a review of promising research and recommendations. *Alternative therapies in health and medicine*, 6(3), 2000.
- [10] A. Fugh-Berman and J. M. Cott. Dietary supplements and natural products as psychotherapeutic agents. *Psychosomatic Medicine*, 61(5), 1999.
- [11] P. Houghton and M.-J. Howes. Natural products and derivatives affecting neurotransmission relevant to alzheimers and parkinsons disease. *Neurosignals*, 14(12), 2005.
- [12] M. D. d. Rocha, F. P. D. Viegas, H. C. Campos, P. C. Nicastro, P. C. Fossaluzza, C. A. M. Fraga, E. J. Barreiro, and C. Viegas. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders ii: Alzheimer's disease. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*, 10(2), 2011.
- [13] J. M. B. Filho, K. C. P. Medeiros, M. de F. F. Diniz, L. M. Batista, P. F. Athayde-Filho, M. S. Silva, E. V. d. Cunha, J. R. Almeida, and L. J. Quintans-Júnior. Natural products inhibitors of the enzyme acetylcholinesterase. *Revista Brasileira de Farmacognosia*, 16(2), 2006.
- [14] M. Citron, T. Oltersdorf, C. Haass, L. McConlogue, A. Y. Hung, P. Seubert, C. Vigo-Pelfrey, I. Lieberburg, and D. J. Selkoe. Mutation of the β -amyloid precursor protein in familial alzheimer's disease increases β -protein production. *Nature*, 360(6405), 1992.
- [15] J. A. Hardy and G. A. Higgins. Alzheimer's disease: the amyloid cascade hypothesis. *Science*, 256(5054), 1992.
- [16] C. A. McLean, R. A. Cherny, F. W. Fraser, S. J. Fuller, M. J. Smith, K. Vbeyreuther, A. I. Bush, and C. L. Masters. Soluble pool of $a\beta$ amyloid as a determinant of severity of neurodegeneration in alzheimer's disease. *Annals of neurology*, 46(6), 1999.
- [17] W. L. Klein. Synaptotoxic amyloid- b oligomers: a molecular basis for the cause, diagnosis, and treatment of alzheimers disease. *J. Alzheimers Dis*, 33, 2013.
- [18] J. D. l. Torre and T. Mussivand. Can disturbed brain microcirculation cause alzheimer's disease? *Neurological research*, 15(3), 1993.
- [19] F. Mawanda and R. Wallace. Can infections cause alzheimer's disease? *Epidemiologic reviews*, 35(1), 2013.
- [20] K. Ikeda, H. Akiyama, H. Kondo, T. Arai, N. Arai, and S. Yagishita. Numerous glial fibrillary tangles in oligodendroglia in cases of subacute sclerosing panencephalitis with neurofibrillary tangles. *Neuroscience letters*, 194(1), 1995.
- [21] T. Mandybur. The distribution of alzheimer's neurofibrillary tangles and gliosis in chronic subacute sclerosing panencephalitis. *Acta neuropathologica*, 80(3), 1990.
- [22] Y. Kueh and G. Devathasan. Amyloid neuropathy in a woman with tabes dorsalis. *The New England journal of medicine*, 310(12), 1984.
- [23] P. P. Liberski. Transmissible cerebral amyloidosis as a model for alzheimers disease. *Molecular neurobiology*, 8(1), 1994.

- [24] A. Kobayashi, K. Arima, M. Ogawa, M. Murata, T. Fukuda, and T. Kitamoto. Plaque-type deposition of prion protein in the damaged white matter of sporadic creutzfeldt-jakob disease mm1 patients. *Acta neuropathologica*, 116(5), 2008.
- [25] B. Sikorska, P. Liberski, T. Sobow, H. Budka, and J. Ironside. Ultrastructural study of florid plaques in variant creutzfeldt-jakob disease: a comparison with amyloid plaques in kuru, sporadic creutzfeldt-jakob disease and gerstmann-strussler-scheinker disease. *Neuropathology and applied neurobiology*, 35(1), 2009.
- [26] F. D. Beer, A. Nel, R. Gie, P. Donald, and A. Strachan. Serum amyloid a protein and c-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis. *Thorax*, 39(3), 1984.
- [27] L. Looi, P. Jayalakshim, K. Lim, and K. Rajagopalan. An immunohistochemical and morphological study of amyloidosis complicating leprosy in malaysian patients. *Annals of the Academy of Medicine, Singapore*, 17(4), 1988.
- [28] C. Rcken, D. Radun, B. Glasbrenner, P. Malfertheiner, and A. Roessner. Generalized aa-amyloidosis in a 58-year-old caucasian woman with an 18-month history of gastrointestinal tuberculosis. *Virchows Archiv*, 434(1), 1999.
- [29] A. G. Wangel, O. Wegelius, and A. E. Dyrting. A family study of leprosy: subcutaneous amyloid deposits and humoral immune responses. *International Journal of Leprosy and Other Mycobacterial Diseases*, 50(1), 1982.
- [30] S. J. Tank, R. S. Chima, V. Shah, S. Malik, S. Joshi, and R. H. Mazumdar. Renal amyloidosis following tuberculosis. *The Indian Journal of Pediatrics*, 67(9), 2000.
- [31] B. A. Urban, E. K. Fishman, S. Goldman, W. S. Jr, B. Jones, R. Humphrey, and R. Hruban. Ct evaluation of amyloidosis: spectrum of disease. *Radiographics*, 13(6), 1993.
- [32] S. J. Soscia, J. E. Kirby, K. J. Washicosky, S. M. Tucker, M. Ingelsson, B. Hyman, M. A. Burton, L. E. Goldstein, S. Duong, R. E. Tanzi, et al. The alzheimer’s disease-associated amyloid β -protein is an antimicrobial peptide. 2010.
- [33] K. Watanabe, K. Matsuura, P. Gao, L. Hottenbacher, H. Tokunaga, K. Nishimura, Y. Imazu, H. Reissenweber, and C. M. Witt. Traditional japanese kampo medicine: clinical research between modernity and traditional medicine the state of research and methodological suggestions for the future. *Evidence-Based Complementary and Alternative Medicine*, 2011, 2011.
- [34] K. Terasawa. Evidence-based reconstruction of kampo medicine: part iis kampo cam? *Evidence-Based Complementary and Alternative Medicine*, 1(1), 2004.
- [35] K. Iwasaki, T. Satoh-Nakagawa, M. Maruyama, Y. Monma, M. Nemoto, N. Tomita, H. Tanji, H. Fujiwara, T. Seki, M. Fujii, et al. A randomized, observer-blind, controlled trial of the traditional chinese medicine yi-gan san for improvement of behavioral and psychological symptoms and activities of daily living in dementia. *Journal of Clinical Psychiatry*, 66(2), 2005.
- [36] H. Okamoto, M. Iyo, K. Ueda, C. Han, Y. Hirasaki, and T. Namiki. Yokukan-san: a review of the evidence for use of this kampo herbal formula in dementia and psychiatric conditions. *Neuropsychiatric disease and treatment*, 10, 2014.
- [37] Y. Matsuda, T. Kishi, H. Shibayama, and N. Iwata. Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. *Human Psychopharmacology: Clinical and Experimental*, 28(1), 2013.
- [38] K. Mizukami. Kampo therapy and behavioral and psychological symptoms of dementia. *Traditional & Kampo Medicine*, 1(2), 2014.

- [39] K. Mizukami, T. Asada, T. Kinoshita, K. Tanaka, K. Sonohara, R. Nakai, K. Yamaguchi, H. Hanyu, K. Kanaya, T. Takao, et al. A randomized cross-over study of a traditional japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. *International Journal of Neuropsychopharmacology*, 12(2), 2009.
- [40] Y. Hayashi, Y. Ishida, T. Inoue, M. Udagawa, K. Takeuchi, H. Yoshimuta, K. Kiue, Y. Ninomiya, J. Kawano, T. Sameshima, et al. Treatment of behavioral and psychological symptoms of alzheimer-type dementia with yokukansan in clinical practice. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 34(3), 2010.
- [41] Y. Tanaka and T. Sakiyama. Potential usefulness of the kampo medicine yokukansan, containing uncaria hook, for paediatric emotional and behavioural disorders: A case series. *Evidence-Based Complementary and Alternative Medicine*, 2013, 2013.
- [42] K.-K. Chua, A. Wong, P. W. Kwan, J.-X. Song, L.-L. Chen, A. L. Chan, J.-H. Lu, V. Mok, and M. Li. The efficacy and safety of the chinese herbal medicine di-tan decoction for treating alzheimers disease: protocol for a randomized controlled trial. *Trials*, 16(1), 2015.
- [43] T. Niitsu, H. Okamoto, and M. Iyo. Behavioural and psychological symptoms of dementia in an alzheimer’s disease case successfully treated with natural medicine: association with gonadotropins. *Psychogeriatrics*, 13(2), 2013.
- [44] K. Matsumoto, Q. Zhao, Y. Niu, H. Fujiwara, K. Tanaka, S. Sasaki-Hamada, and J.-I. Oka. Kampo formulations, chotosan, and yokukansan, for dementia therapy: existing clinical and preclinical evidence. *Journal of pharmacological sciences*, 122(4), 2013.
- [45] H. Watari, Y. Shimada, and C. Tohda. New treatment for alzheimers disease, kamikihito, reverses amyloid-induced progression of tau phosphorylation and axonal atrophy. *Evidence-Based Complementary and Alternative Medicine*, 2014, 2014.
- [46] H. Watari, M. Shigyo, N. Tanabe, M. Tohda, K.-H. Cho, P. S. Kyung, W. S. Jung, Y. Shimada, N. Shibahara, T. Kuboyama, et al. Comparing the effects of kamikihito in japan and kami-guibi-tang in korea on memory enhancement: Working towards the development of a global study. *Phytotherapy Research*, 29(3), 2015.
- [47] C. Kudoh, R. Arita, M. Honda, T. Kishi, Y. Komatsu, H. Asou, and M. Mimura. Effect of ninjin’yoeito, a kampo (traditional japanese) medicine, on cognitive impairment and depression in patients with alzheimer’s disease: 2 years of observation. *Psychogeriatrics*, 2015.
- [48] H. Kiyohara, K. Nonaka, M. Sekiya, T. Matsumoto, T. Nagai, Y. Tabuchi, and H. Yamada. Polysaccharide-containing macromolecules in a kampo (traditional japanese herbal) medicine, hochuekkito: dual active ingredients for modulation of immune functions on intestinal peyer’s patches and epithelial cells. *Evidence-Based Complementary and Alternative Medicine*, 2011, 2011.
- [49] N. Satoh, S. Sakai, T. Kogure, E. Tahara, H. Origasa, Y. Shimada, K. Kohoda, T. Okubo, and K. Terasawa. A randomized double blind placebo-controlled clinical trial of hochuekkito, a traditional herbal medicine, in the treatment of elderly patients with weakness n of one and responder restricted design. *Phytomedicine*, 12(8), 2005.
- [50] C. Tohda, T. Tamura, and K. Komatsu. Repair of amyloid β (25–35)-induced memory impairment and synaptic loss by a kampo formula, zokumei-to. *Brain research*, 990(1), 2003.
- [51] K. Iwasaki, S. Kobayashi, Y. Chimura, M. Taguchi, K. Inoue, S. Cho, T. Akiba, H. Arai, J.-C. Cyong, and H. Sasaki. A randomized, double-blind, placebo-controlled clinical trial of the chinese herbal medicine ba wei di

- huang wan in the treatment of dementia. *Journal of the American Geriatrics Society*, 52(9), 2004.
- [52] Y. Zhang, C. Lin, L. Zhang, Y. Cui, Y. Gu, J. Guo, D. Wu, Q. Li, and W. Song. Cognitive improvement during treatment for mild alzheimers disease with a chinese herbal formula: A randomized controlled trial. *PloS one*, 10(6), 2015.
- [53] Z.-K. Sun, H.-Q. Yang, and S.-D. Chen. Traditional chinese medicine: a promising candidate for the treatment of alzheimers. 2013.
- [54] N. S. Perry, P. J. Houghton, J. Sampson, A. E. Theobald, S. Hart, M. Lis-Balchin, J. R. S. Hoults, P. Evans, P. Jenner, S. Milligan, et al. In-vitro activity of *s. lavandulaefolia* (spanish sage) relevant to treatment of alzheimer’s disease. *Journal of Pharmacy and pharmacology*, 53(10), 2001.
- [55] E. Yuçe, N. Yildirim, N. Yildirim, M. Paksoy, and E. Bağcı. Essential oil composition, antioxidant and antifungal activities of *salvia sclarea* l. from munzur valley in tunceli, turkey. *Cellular and molecular biology (Noisy-le-Grand, France)*, 60(2), 2014.
- [56] N. Tabanca, B. Demirci, K. H. C. Baser, Z. Aytaç, M. Ekici, S. I. Khan, M. R. Jacob, and D. E. Wedge. Chemical composition and antifungal activity of *salvia macrochlamys* and *salvia recognita* essential oils. *Journal of agricultural and food chemistry*, 54(18), 2006.
- [57] T. Seki, T. Kamiya, M. Azumi, S. Ishizuka, K. Furukawa, T. Yamakuni, and K. Meguro. Nobiletin-rich citrus reticulata peels for alzheimer’s disease. *Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association*, 4(9), 2013.
- [58] C. S.-W. Lai, M.-S. Yu, W.-H. Yuen, K.-F. So, S.-Y. Zee, and R. C.-C. Chang. Antagonizing β -amyloid peptide neurotoxicity of the anti-aging fungus *ganoderma lucidum*. *Brain research*, 1190, 2008.
- [59] Y. Zhou, Z. q. Qu, Y. s. Zeng, Y. k. Lin, Y. Li, P. Chung, R. Wong, and U. Hgg. Neuroprotective effect of preadministration with *ganoderma lucidum* spore on rat hippocampus. *Experimental and Toxicologic Pathology*, 64(7), 2012.
- [60] I. Lee, B. Ahn, J. Choi, M. Hattori, B. Min, and K. Bae. Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of *ganoderma lucidum*. *Bioorganic & medicinal chemistry letters*, 21(21), 2011.
- [61] W.-J. Li, S.-P. Nie, M.-Y. Xie, Q. Yu, Y. Chen, and M. He. *Ganoderma atrum* polysaccharide attenuates oxidative stress induced by d-galactose in mouse brain. *Life sciences*, 88(15), 2011.
- [62] M.-F. Wang, Y.-C. Chan, C.-L. Wu, Y.-C. Wong, K. Hosoda, and S. Yamamoto. Effects of *ganoderma* on aging and learning and memory ability in senescence accelerated mice. In *International Congress Series*, volume 1260, 2004.
- [63] R. Alonso, D. Pisa, A. I. Marina, E. Morato, A. Rábano, and L. Carrasco. Fungal infection in patients with alzheimer’s disease. *Journal of Alzheimer’s disease: JAD*, 41(1), 2013.
- [64] D. Pisa, R. Alonso, A. Rábano, I. Rodal, and L. Carrasco. Different brain regions are infected with fungi in alzheimers disease. *Scientific reports*, 5, 2015.
- [65] C. Soto, L. Estrada, and J. Castilla. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. *Trends in biochemical sciences*, 31(3), 2006.
- [66] M. Hauwel, E. Furon, C. Canova, M. Griffiths, J. Neal, and P. Gasque. Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, protective glial stem cells and stromal ependymal cells. *Brain research reviews*, 48(2), 2005.
- [67] S. Treusch, S. Hamamichi, J. L. Goodman, K. E. Matlack, C. Y. Chung, V. Baru, J. M.

- Shulman, A. Parrado, B. J. Bevis, J. S. Valastyan, et al. Functional links between $\alpha\beta$ toxicity, endocytic trafficking, and alzheimers disease risk factors in yeast. *Science*, 334(6060), 2011.
- [68] M. F. Gebbink, D. Claessen, B. Bouma, L. Dijkhuizen, and H. A. Wsten. Amyloids a functional coat for microorganisms. *Nature reviews microbiology*, 3(4), 2005.
- [69] P. M. Tessier and S. Lindquist. Unraveling infectious structures, strain variants and species barriers for the yeast prion $[\psi^+]$. *Nature structural & molecular biology*, 16(6), 2009.
- [70] T. K. Means, E. Mylonakis, E. Tampakakis, R. A. Colvin, E. Seung, L. Puckett, M. F. Tai, C. R. Stewart, R. Pukkila-Worley, S. E. Hickman, et al. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors scarf1 and cd36. *The Journal of experimental medicine*, 206(3), 2009.
- [71] T. Nrnberger and F. Brunner. Innate immunity in plants and animals: emerging parallels between the recognition of general elicitors and pathogen-associated molecular patterns. *Current opinion in plant biology*, 5(4), 2002.
- [72] T. Nrnberger, F. Brunner, B. Kemmerling, and L. Piater. Innate immunity in plants and animals: striking similarities and obvious differences. *Immunological reviews*, 198(1), 2004.
- [73] S. Akira, S. Uematsu, and O. Takeuchi. Pathogen recognition and innate immunity. *Cell*, 124(4), 2006.
- [74] K. Fassbender, S. Walter, S. Khl, R. Landmann, K. Ishii, T. Bertsch, A. Stalder, F. Muehlhauser, Y. Liu, A. Ulmer, et al. The lps receptor (cd14) links innate immunity with alzheimers disease. *The FASEB Journal*, 18(1), 2004.
- [75] S. Bellocchio, C. Montagnoli, S. Bozza, R. Gaziano, G. Rossi, S. S. Mambula, A. Vecchi, A. Mantovani, S. M. Levitz, and L. Romani. The contribution of the toll-like/il-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. *The Journal of Immunology*, 172(5), 2004.
- [76] S. Viriyakosol, J. Fierer, G. D. Brown, and T. N. Kirkland. Innate immunity to the pathogenic fungus *coccidioides posadasii* is dependent on toll-like receptor 2 and dectin-1. *Infection and immunity*, 73(3), 2005.
- [77] H. Kumar, T. Kawai, and S. Akira. Pathogen recognition by the innate immune system. *International reviews of immunology*, 30(1), 2011.
- [78] A. Salminen, J. Ojala, A. Kauppinen, K. Kaarniranta, and T. Suuronen. Inflammation in alzheimer's disease: amyloid- β oligomers trigger innate immunity defence via pattern recognition receptors. *Progress in neurobiology*, 87(3), 2009.
- [79] B. A. I. Veld, A. Ruitenber, A. Hofman, L. J. Launer, C. M. van Duijn, T. Stijnen, M. M. Breteler, and B. H. Stricker. Nonsteroidal anti-inflammatory drugs and the risk of alzheimer's disease. *New England Journal of Medicine*, 345(21), 2001.
- [80] M. T. Heneka and M. K. O'Banion. Inflammatory processes in alzheimer's disease. *Journal of neuroimmunology*, 184(1), 2007.
- [81] C. Requena, F. Maestu, P. Campo, A. Fernandez, and T. Ortiz. Effects of cholinergic drugs and cognitive training on dementia: 2-year follow-up. *Dementia and geriatric cognitive disorders*, 22(4), 2006.
- [82] J. O'Brien, J. W. Jackson, F. Grodstein, D. Blacker, and J. Weuve. Postmenopausal hormone therapy is not associated with risk of all-cause dementia and alzheimer's disease. *Epidemiologic reviews*, 36(1), 2014.